Survival Rates for TP53-Mutated MDS Improves With Allogeneic HCT
Study results suggest that patients with myelodysplastic syndrome have the potential to benefit from HCT regardless of their genetic mutations.
Benefits and Efficiencies Abound, but AI Misses the Humanity of Care
FDA Approves Luspatercept-aamt for Upfront Treatment of Anemia in Lower-Risk MDS
The FDA has added to the existing approval of luspatercept-aamt for the treatment of patients with anemia and lower-risk myelodysplatic syndrome.
Ofatumumab-Based Regimens Improve Survival in CLL
Combination therapies utilizing ofatumumab could improve outcomes for patients with chronic lymphocytic leukemia, according to an analysis published in the Annals of Hematology.
Unmet Needs in Oligometastatic Prostate Cancer
Chad Tang, MD, discusses ongoing challenges for the treatment of patients with oligometastatic prostate cancer.
ME-344 Plus Bevacizumab Therapy Begins in Patients With Previously-Treated mCRC
Treatment with an investigational mitochondrial inhibitor and bevacizumab has started in a phase 1b clinical trial of patients with previously-treated metastatic colorectal cancer.
Phase 3 Trial of TTFields and Paclitaxel Misses OS End Point in Ovarian Cancer
The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.
Neoadjuvant Immunotherapy for Stage III Melanoma Emerges as New Standard of Care
The phase 2 SWOG S1801 trial showed a 42% reduction in 2-year event-free survival for neoadjuvant-adjuvant vs adjuvant-only pembrolizumab for resectable stage IIIB-D/IV melanoma.
Ivonescimab Challenges Tislelizumab Plus Chemo in Advanced, EGFR+ NS-NSCLC
Ivonescimab is being investigated in phase 3 clinical trial against the combination of tislelizumab and chemotherapy.
Adding Durvalumab to Perioperative Chemo Shows Promising EFS, OS in MIUC
A single-arm trial induced high event-free and overall survival with the addition of durvalumab to standard of care before radical surgery in patients with muscle-invasive urothelial carcinoma.
LEAP-010 Study Discontinued for Patients with PD-L1-Expressing HNSCC
A coprimary end point in the phase 3 LEAP-010 study will not be met.
FDA Approval Sought for Upfront Amivantamab/Chemo in Advanced EGFR Exon20Ins Mut+ NSCLC
Based on positive phase 3 PAPILLON results, an application for a new approval for amivantamab has been filed with the FDA.
Overcoming Resistance in Gastrointestinal Cancers
Immune checkpoint inhibitors are approved for dMMR/MSI-H gastrointestinal cancer treatment; however, approximately half of patients with dMMR/MSI-H gastrointestinal cancer exhibit primary resistance to them.
Ivonescimab Plus Chemo Shows Antitumor Activity, Safety in Advanced NSCLC
Frontline treatment with AK112, a first-in-class humanized IgG1 bispecific antibody, plus chemotherapy demonstrated promising overall responses across 3 cohorts in a phase 2 trial.
Could VAL-083 Address Modest Treatment Efficacy in Glioblastoma?
Experts believe VAL-083 has the potential to change the way oncologists treat glioblastoma in the future.
FDA Elevates Novel Targeted Therapies in Solid Tumors
Novel agents are now under development for newly druggable targets in patients with solid tumors.
NXC-201 Awarded Orphan Drug Designation for Multiple Myeloma Treatment
FDA notices NXC-201 for its potential offer a novel mechanism to treat patients with multiple myeloma.
Favorable Immune Profile Linked to VT1021 Treatment Response in rGBM
Patients treated with VT1021 for recurrent glioblastoma were found to have immune markers associated with response to treatment in a phase 1/2 study.
An Abundance of Approaches Moves Discussion of Sequencing to the Forefront in MM
During an Oncology Town Hall™ virtual meeting, 4 investigators in multiple myeloma addressed emerging therapies, optimal sequencing, the role of minimal residual disease to inform therapy, and the possibility of storing T cells for use in later CAR T-cell therapy.
Neratinib Combo Shows Substantial Benefit in HER2-Mutant mBC
According to Manali Bhave, MD, neratinib plus fulvestrant plus trastuzumab and should be considered as a therapeutic option with clinically meaningful benefit in patients with HER2-mutant metastatic breast cancer.
Selpercatinib Extends PFS in Advanced/Metastatic, RET-Mutant MTC
According to Marcia Brose, MD, PhD, FASCO, interim findings from the phase 3 LIBRETTO-531 trial confirms the benefit of selpercatinib in patients with advanced, RET-mutant medullary thyroid cancer.
Tarlatamab Shows Antitumor Activity, Safety in Small Cell Lung Cancer
The DeLLphi-300 trial of a bispecific T-cell engager showed favorable outcomes in patients with previously treated small cell lung cancer.
FDA to Quickly Review sNDA for Enzalutamide in nmCSPC With High-Risk BCR
The metastasis-free survival benefit of enzalutamide, and other efficacy and safety data are now under FDA review for the potential approval of the drug for patients with non-metastatic castration-sensitive prostate cancer.
Clinically Meaningful Activity Is Observed for Liso-Cel in Relapsed/Refractory MCL
Lisocabtagene maraleucel showed activity in patients with relapsed/refractory mantle cell lymphoma, according to findings from the TRANSCEND-NHL-001 study.
Sacituzumab Govitecan Continues to Show Efficacy in Pretreated mUC
In an interview with Targeted Oncology, Daniel P. Petrylak, MD, discussed findings from the TROPHY-U-01 study for patients with mUC, and what the next steps for research are.
FDA to Review Imetelstat NDA for Transfusion-Dependent Anemia in Lower-Risk MDS
On the heels of promising findings from the phase 3 IMerge study, the FDA has accepted the new drug application of imetelstat for transfusion-dependent anemia in patients with lower-risk MDS.
Ibrutinib Combo Shows Improved Duration of Response in rFL/MZL
The combination of ibrutinib with chemoimmunotherapy improved the duration of response for a subset of patients with relapsed follicular lymphoma and marginal zone lymphoma.
Cabozantinib Plus Atezolizumab Prolongs Survival in mCRPC Subgroup
A primary end point has been met in the phase 3 CONTACT-02 clinical trial.
Activity Observed With Cabozantinib/Nivolumab/Ipilimumab in RCCvh
In an interview with Targeted Oncology, Bradley A. McGregor, MD, discussed the main takeaways from a phase 3 study of cabozantinib, nivolumab, and ipilimumab for patients with renal cell carcinoma with variant histologies.
FDA Pauses Magrolimab Studies in Acute Myeloid Leukemia
A pause on trials of magrolimab in acute myeloid leukemia will affect the screening and enrollment of patients.
2 Clarke Drive Cranbury, NJ 08512